^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CYAD-101

    i
    Other names: CYAD-101, non-gene edited allogeneic CAR-T, TIM8-CYAD-01
    Company:
    Celyad Oncology
    Drug class:
    NKG2DL-targeted CAR-T immunotherapy
    Related drugs:
    almost3years
    KEYNOTE-B79: Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=34, Recruiting, Celyad Oncology SA | Not yet recruiting --> Recruiting | Phase classification: P1b --> P1
    Enrollment open • Phase classification
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • CYAD-101
    over3years
    Phase 1b Study to Evaluate the Addition of a Pembrolizumab Treatment After Treatment With CYAD-101 With a FOLFOX Preconditioning in Metastatic Colorectal Cancer Patients (clinicaltrials.gov)
    P1b, N=34, Not yet recruiting, Celyad Oncology SA
    New P1 trial
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • CYAD-101
    over4years
    [VIRTUAL] CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy. (ASCO 2020)
    Fifteen refractory metastatic CRC patients who had previously failed at least one line of oxaliplatin—containing therapy were treated with three doses of CYAD-101 cells given on Day 3 of three successive FOLFOX chemotherapy cycles. These early clinical results demonstrate the safety and tolerability of a non-gene edited predominantly CD4+ CAR-T therapeutic approach. The initial observations of clinical activity in metastatic CRC patients warrants the continued development of this therapy. Research Funding: Celyad SA
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • CD27 (CD27 Molecule) • NKG2D (killer cell lectin like receptor K1)
    |
    LAG3 expression
    |
    oxaliplatin • CYAD-101